ArticleArchives of medical science : AMS2019
Evaluation of endocan and endoglin levels in chronic kidney disease due to diabetes mellitus.
Article in Archives of medical science : AMS, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- High circulating endocan in chronic kidney disease? A systematic review and meta-analysis.PloS one · 2023Pooled it
- Endocan level and its association with glycemic and inflammatory indices in diabetic nephropathy.BMC endocrine disorders · 2026Article
- Evaluation of Serum Endocan and Testosterone Levels in Male Patients with Prediabetes: A Cross-Sectional Clinical Study.Journal of clinical medicine · 2026Article
- Clinical relevance of circulating endocan and endoglin in excess body weight-associated endothelial dysfunction.Frontiers in cardiovascular medicine · 2026Article
- Novel prognostic impact and cell specific role of endocan in patients with coronary artery disease.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Association of plasma endocan levels with metabolic parameters and predictive value of endocan for the development of complications in patients with type 2 diabetes mellitus: An observational study.Biomolecules & biomedicine · 2025Observational
- Mesenchymal stem cells suppress kidney injury molecule-1 associated with inhibition of renal PKC/NF-Kβ/STAT3 fibrotic signaling pathway in rats with diabetic nephropathy.Archives of medical science : AMS · 2025Article
- Endocan, a novel glycoprotein with multiple biological activities, may play important roles in neurological diseases.Frontiers in aging neuroscience · 2024Review
- Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2023Article
- The Role of Endocan in Cardiometabolic Disorders.Metabolites · 2023Review
- Endocan, a Soluble Marker of Endothelial Cell Activation Is a Molecular Marker of Disease Severity in Women with Preeclampsia.Reproductive sciences (Thousand Oaks, Calif.) · 2022Article
- Methods to evaluate vascular function: a crucial approach towards predictive, preventive, and personalised medicine.The EPMA journal · 2022Review
- Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases.International journal of clinical practice · 2022Article
- Prognostic and Diagnostic Value of Endocan in Kidney Diseases.International journal of nephrology · 2022Review
- Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells.Frontiers in medicine · 2022Article
- Membrane and soluble endoglin role in cardiovascular and metabolic disorders related to metabolic syndrome.Cellular and molecular life sciences : CMLS · 2021Review
- Serum endocan levels in relation to traditional and non-traditional anthropometric indices in adult population.Journal of medical biochemistry · 2021Article
- Endocan: A Key Player of Cardiovascular Disease.Frontiers in cardiovascular medicine · 2021Review
- Mechanism of tangshen formula in treating diabetic nephropathy revealed by network pharmacology approach.Archives of medical science : AMS · 2021Article
- Is endocan a novel potential biomarker of liver steatosis and fibrosis?Journal of medical biochemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEndocan and endoglin have been shown to play a role in angiogenesis. Aberrant excessive angiogenesis is a main factor in the development of diabetic nephropathy. In this study we evaluated endocan and endoglin levels in diabetes patients with and without albuminuria and compared them with healthy subjects. Therefore we aimed at gaining a better understanding of the role of angiogenesis in diabetic nephropathy and to assess the predictive role of endocan and endoglin as markers of diabetic nephropathy progression. MATERIAL AND
methodsNinety-six type 2 diabetes patients were classified according to their 24-hour urinary albumin excretion rate. Forty type 2 diabetes patients with normoalbuminuria (urinary albumin excretion < 30 mg/day), 56 type 2 diabetes patients with diabetic nephropathy (with a urinary albumin excretion ≥ 30 mg/day) and 35 healthy non-diabetic control subjects were included. Their anthropometric features, arterial blood pressures, fasting glucose, glycated hemoglobin, urea, creatinine, lipids, endocan and endoglin levels were measured and compared to each other.
resultsEndocan and endoglin levels of diabetics patients were higher than those of the controls. In comparison of endocan and endoglin levels of diabetic nephropathy patients with controls,
conclusionsEndocan might be a more reliable marker of diabetic nephropathy development than endoglin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.